Comparison
Hexarelin vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
140703-51-1
910463-68-2
Molecular weight
887.05 g/mol
4113.6 g/mol
Half-life
0.9 h
165 h
Sequence
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
3
3
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
5